Novo Nordisk A/S
Long

NVO - buying quality compounder during panic

168
Financials great, P/E 20 is very reasonable. Top line 20%+, LLY competition threats seems exaggerated. Last time was this oversold in 2017 and quickly rebounded. Impossible to replicate knowledge and ability to innovate. Started entry position at 78.5, will be DCA until it finds the bottom (if not already)

Happy weekend

Clause de non-responsabilité

Les informations et les publications ne sont pas destinées à être, et ne constituent pas, des conseils ou des recommandations en matière de finance, d'investissement, de trading ou d'autres types de conseils fournis ou approuvés par TradingView. Pour en savoir plus, consultez les Conditions d'utilisation.